Dr. Christopher R. Flowers explains that MRD testing varies by cancer type, with results impacting recurrence risk and ...

In this video, Arvind Dasari, MD, MS, discussed data from multiple ASCO Gastrointestinal Cancers Symposium presentations highlighting the use of ctDNA as a minimal residual disease in colorectal ...

Foresight Diagnostics Inc., a Boulder-based cancer diagnostics company that specialized in the development of ultra-sensitive minimal residual disease, or MRD, detection, recently expanded its ...

Patients who received cilta-cel had improvements in progression-free survival and overall survival if they had sustained a minimal residual disease-negative complete response or better for at least 1 ...

Idecabtagene vicleucel induced high complete response and minimal residual disease negativity rates in multiple myeloma after ...

Discover how ctDNA revolutionizes multiple myeloma monitoring, tracking disease progression, and improving personalized ...

Allogene Therapeutics expands collaboration with Foresight Diagnostics to advance development activities in Europe, UK, Canada & Australia: South San Francisco, California Thursda ...

The CRISTALLO trial showed that venetoclax plus obinutuzumab achieved high minimal residual disease negativity as a frontline ...

The "Genomic Reference Materials and Controls Systems Market: Focus on Product Type, Application, End User, and Country-Level Analysis - Analysis and Forecast, 2025-2035" report has been added to ...